1st Quarter - Report

SOCIETY FOR MATERNAL-FETAL MEDICINE for SOCIETY FOR MATERNAL-FETAL MEDICINE

Firm
Client
Income
—
Expenses
$20,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Preventing Maternal Deaths Act (HR 1318/), Maternal Health Accountability Act (S. 1112), pre-term birth, maternal mental health, Quality Care for Moms and Babies Act (S. 2367/HR 5457), Improving Access to Maternity Care Act (S. 783, HR 315); pregnancy research.

LobbyistCovered position, as disclosed
KATHRYN SCHUBERT —

Contacted: Natl Institutes of Health (NIH); SENATE; Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA)

Bills named: H.R. 1318 (115th), H.R. 5457 (115th), S. 1112 (115th), S. 783 (115th), S. 2367 (115th), H.R. 315 (115th)

Budget/Appropriations BUD

Labor-HHS-Education Appropriations bill FY2018, Labor-HHS-Education Appropriations bill FY2019, FDA funding, maternal-fetal medicine research; sequestration and non-defense discretionary funding; maternal mental health; opioids; family planning/Title X; Zika; pre-term birth; pregnancy surveillance; reproductive health service; health services research.

LobbyistCovered position, as disclosed
KATHRYN SCHUBERT —

Contacted: Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA); SENATE; Centers For Disease Control & Prevention (CDC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.